about
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolLEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropeniaMolecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayTumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapyPolymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2Ap-BioSPRE-an information and communication technology framework for transnational biomaterial sharing and accessVariation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotypeMetastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemiaVariation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia riskSmall sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia.A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymesLow platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcomePrediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaGenomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology.Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemiaSecond malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.Characterization of leukemias with ETV6-ABL1 fusionTreatment of childhood acute lymphoblastic leukemia.CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group.GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group.S100-alarmin-induced innate immune programming protects newborn infants from sepsis.Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
P50
Q23749304-764151D6-B66A-4835-85EF-13EABBBA6BA5Q24309133-21BC7570-ADAB-4177-821A-B4E2B9D90D4EQ24650855-9A147904-B395-4D23-A132-5D12280EBAAAQ24798344-5798311E-27E5-477C-A353-7909502C45B8Q24814207-18AF8FCF-4FBC-4BCA-ADF7-F81E70F3CAAEQ27852750-996912B2-60FE-43A9-B058-A58541F82DD2Q28391081-5FFCDF0E-7120-4C9D-8131-15C2773D31DFQ28659199-4DA93575-9A13-4949-AD3A-BE5B3D62E715Q28943255-95A2DBBB-1491-4AF7-98B9-129851C5D0C0Q33865098-41C81263-EC81-4B37-B34B-D772463BA049Q34066349-B65638D2-213B-4AEE-9E56-75EA9E172F05Q34114297-4946EBFA-90A6-4EC0-A38C-6347A39B0769Q34325528-28E1FAFA-36A5-4597-B79B-8AFA74AA1732Q34973772-7E4C6BD7-8353-4C61-B4BD-5F565B6E01F3Q35082533-66E82CDA-CCD2-45D3-8957-82F873952949Q35647066-1ED655A7-9FF8-4D7E-B380-3028BE65B590Q35794444-F675B05E-C6C8-494E-AF93-D5E51305832BQ36094717-F5B18C07-DE90-4903-8D37-BFFF6ED99F14Q36154689-FCA929F8-3E5F-4BDC-9DE9-B92289E61849Q36582277-C27650BC-4560-47E6-ADF6-B7B6E6724380Q36833122-9E567049-9855-4250-8746-B5D485E44828Q36862420-C2DF5A7D-8B75-4860-9516-B099ACC5F488Q36892602-7AD9CB52-0C27-4C71-A85E-1F62B2C1CA73Q36954396-88FAA259-A315-4A00-B873-EB69F9255A2EQ37246514-068F5778-D3DE-4EBB-95B3-5B1F93D18A39Q37252283-152E66C7-88C1-425B-817E-B5F8011240B7Q37331221-3988B0DB-6CC4-4E49-9B2B-223C1FF2F3BFQ37355973-C13DCA7B-B4BA-496E-A634-66E27C108E98Q37644852-EDE3943B-80FB-4577-A7B5-46EC1CDECB14Q37779336-E75B6B00-D413-408D-A34A-27D05661C1FEQ38470579-40B822FF-3125-4925-8579-B7C1BF2B3D88Q38665804-D1809556-C6DF-4DA2-A498-08FCFCACB965Q38677717-DBCBEF99-EBE9-4C7B-9430-188808F2703FQ38811341-7EC42A96-8EAC-4D6D-B25B-6A4DAA56279DQ38839019-5A570409-BD1F-45CE-8627-D2BC2F2243BEQ38858845-13E6F457-9D5E-4F7D-AB73-3FEB9DDB9447Q38951206-994865D9-B112-4698-97B0-0F9A6293AB0CQ39766394-0DEDF540-51A7-4E0A-9B01-1BB90DFA97DFQ39835436-F6F9AE5D-E3D2-4615-8D6E-58A7E1113BA1Q39889099-10110168-09B7-401E-9CBB-6C3A8864363E
P50
name
Martin Stanulla
@en
Martin Stanulla
@nl
type
label
Martin Stanulla
@en
Martin Stanulla
@nl
prefLabel
Martin Stanulla
@en
Martin Stanulla
@nl